Position of the Transparency Council – Vyepti (eptinezumab)
At its meeting on 24 February 2025, the Transparency Council adopted position No. 22/2025 on the evaluation of the drug Vyepti (eptinezumab) under the drug program B.133 “Prophylactic treatment of patients with chronic migraine (ICD-10: G43)”.